Skip to content

Stock Markets Show Recovery Signs as COVID-19 Drug Appears Effective

Stock Markets Show Recovery Signs as COVID-19 Drug Appears Effective (2)
Martin Young

Global stock markets have mostly spent the week consolidating, however, things started to move on Thursday as reports that a drug used to treat coronavirus has started to show effectiveness.

US stock futures rallied following a report that said a Gilead Sciences drug was showing effectiveness in treating the coronavirus. The California headquartered firm is a biotechnology company that researches develops and commercializes drugs. Its primary focus is on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza.

Coronavirus Drug Success Hopes

CNN reported that patients receiving an experimental drug called ‘Remdesivir’ have been recovering quickly, with most returning to their homes in days. The U.S. National Institutes of Health is organizing trials of several drugs and other treatments though there is no known cure for COVID-19 yet.

Dow Jones Industrial Average futures were up 827 points, which implies a Friday opening gain of about 814 points according to CNBC. Shares in Gilead surged 16.4% in after-hours trading following the reports of the drug’s successes.

The S&P 500 has jumped more than 25% since late March while the Dow has gained almost 27% over the same period. The Federal Reserve’s rate cut to zero also boosted stock markets along with a multi-trillion dollar stimulus plan.

S&P 500 performance, last 12 months. FinViz data.

The WSJ reported that Asian markets were already showing positive signs in early trading on Friday. In Australia’s S&P/ASX 200, Japan’s Nikkei 225 and South Korea’s Kospi all climbed rose by around 2 to 3 percent each, while the Shanghai Composite Index added 0.8%.

China’s economy continues to weaken with a 6.8% shrink in the first quarter compared to the same period last year. It has been the first decline since GDP records began in 1992 according to Reuters. GDP fell 9.8% on a quarter-on-quarter basis, from January to March.

Commodities Outlook

Commodities have been a mixed bag this week with crude oil prices continuing to slump while gold remains bullish. Gold prices hit a new seven-year high on Tuesday when they reached $1,756 USD/oz. Currently, the commodity is being traded at $1,713 USD/oz according to FinViz.

Gold price performance, last 12 months, daily chart. FinViz data.

The precious yellow metal is continuing to act as a safe haven in times of economic turmoil and continued lockdowns across the globe.

Oil continues to decline with West Texas Intermediate crude failing to find support at the key $20 a barrel mark this week. Economic and industrial shut down has diminished the demand for oil and OPEC has slashed its expectations for crude demand for 2020.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Read Next:

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account? Sign In

Services

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.